LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Señales de momentum (gestores comparables):
amplitud de titulares +4.0% ·
flujo de acciones +0.6% ·
nuevas posiciones netas +3.8%
— fórmula
Acumulación amplia — aumento de acciones entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 193 | +4 | 671.92M | $804.91B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | — |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | — |
| Q2 2024 | 22 | — | 112.43M | $101.75B | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (pasivo) | 34.31M | — | $26.49B | 1.0% | n/c | 1 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 20.86M | -0.3% | $16.11B | 1.9% | ▼ Trim | 3 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 20.86M | -0.3% | $16.11B | 1.9% | ▼ Trim | 3 | SEC ↗ |
| 4 | Capital World Investors ✦ | 19.55M | -4.0% | $15.09B | 2.3% | ▼ Trim | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (pasivo) | 17.38M | +1.7% | $13.39B | 1.0% | ▲ Add | 3 | SEC ↗ |
| 6 | Geode Capital Management ✦ (pasivo) | 17.38M | +1.7% | $13.39B | 1.0% | ▲ Add | 3 | SEC ↗ |
| 7 | PRIMECAP Management ✦ | 16.76M | -5.3% | $12.94B | 10.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 9 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 10 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 11 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 12 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 13 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 14 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 15 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 16 | Wellington Management ✦ | 12.63M | +19.0% | $9.75B | 1.8% | ▲ Add | 3 | SEC ↗ |
| 17 | Norges Bank ✦ (pasivo) | 10.89M | +3.9% | $8.41B | 1.1% | ▲ Add | 3 | SEC ↗ |
| 18 | Fisher Asset Management ✦ | 5.24M | +3.5% | $4.04B | 1.6% | ▲ Add | 3 | SEC ↗ |
| 19 | Tiger Global Management ✦ | 1.31M | +35.1% | $1.01B | 3.8% | ▲ Add | 3 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 1.24M | +204.1% | $957.87M | 1.1% | ▲ Add | 3 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 1.24M | +204.1% | $957.87M | 1.1% | ▲ Add | 3 | SEC ↗ |
| 22 | Millennium Management ✦ | 801.07K | -19.1% | $618.42M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 23 | Lone Pine Capital ✦ | 782.86K | Nuevo | $604.37M | 4.5% | New | 1 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 732.55K | -11.7% | $565.53M | 1.0% | ▼ Trim | 3 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 643.94K | -5.0% | $496.17M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 31 | Citadel Advisors ✦ | 611.27K | +184.1% | $471.90M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 32 | Citadel Advisors ✦ | 611.27K | +184.1% | $471.90M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 33 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 34 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 35 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 36 | Marshall Wace ✦ | 388.68K | -57.3% | $300.06M | 0.4% | ▼ Trim | 3 | SEC ↗ |
| 37 | Two Sigma Investments ✦ | 322.69K | +61.6% | $249.12M | 0.6% | ▲ Add | 3 | SEC ↗ |
| 38 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 39 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 40 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 41 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 42 | Coatue Management ✦ | 213.98K | -13.7% | $165.20M | 0.6% | ▼ Trim | 3 | SEC ↗ |
| 43 | Bridgewater Associates ✦ | 84.36K | +15.1% | $65.12M | 0.3% | ▲ Add | 3 | SEC ↗ |
| 44 | Duquesne Family Office ✦ | 62.19K | Nuevo | $48.01M | 1.4% | New | 1 | SEC ↗ |
| 45 | Renaissance Technologies ✦ | 54.12K | -79.0% | $41.78M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 46 | Dodge & Cox ✦ | 44.80K | -0.7% | $34.58M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 47 | Soros Fund Management ✦ | 33.64K | Nuevo | $25.97M | 0.7% | New | 1 | SEC ↗ |
| 48 | GAMCO Investors ✦ | 33.54K | -3.6% | $25.90M | 0.3% | ▼ Trim | 3 | SEC ↗ |
| 49 | Arrowstreet Capital ✦ | 14.85K | -99.1% | $11.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 50 | Gotham Asset Management ✦ | 5.78K | -32.1% | $4.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Lone Pine Capital | $604.37M | 4.5% |
| Duquesne Family Office | $48.01M | 1.4% |
| Soros Fund Management | $25.97M | 0.7% |
Posición cerrada
| Viking Global Investors | $134.70M | era 0.5% |
| Point72 Asset Management | $11.66M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 4,323 tenedores, 762.84M acciones, $674.93B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 6.50K acc. · $7.64M
Officer · 2.00K acc. · $2.37M
Officer · 5.00K acc. · $5.95M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…
ForbesThe Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…
WSJThe U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help identify signs of…
ReutersThe once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…
WSJEli Lilly said on Monday it has launched its oral pill, Foundayo, in the UK for weight management and type 2…
Reuters